Get the Stockscreener App
0.0201
33.00%
-0.0099
After Hours:
.02
-0.000100
-0.50%
Windtree Therapeutics Inc stock is traded at $0.0201, with a volume of 575.48K.
It is down -33.00% in the last 24 hours and down -66.44% over the past month.
WINDTREE THERAPEUTICS NEW
See More
Previous Close:
$0.03
Open:
$0.02195
24h Volume:
575.48K
Relative Volume:
7.97
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-14.67M
P/E Ratio:
-0.000092
EPS:
-218.8129
Net Cash Flow:
$-15.19M
1W Performance:
-33.00%
1M Performance:
-66.44%
6M Performance:
-97.23%
1Y Performance:
-98.94%
1-Day Range:
$0.0192
$0.0225
1-Week Range:
$0.0192
$0.0225
52-Week Range:
$0.0192
$0.19
Windtree Therapeutics Inc Stock (WINT) Company Profile
Name
Windtree Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare WINT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WINT
Windtree Therapeutics Inc
|
0.0201 | 0 | 0 | -14.67M | -15.19M | -218.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Windtree Therapeutics Inc Stock (WINT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-26-20 | Initiated | Ladenburg Thalmann | Buy |
Windtree Therapeutics Inc Stock (WINT) Latest News
Resistance Check: Why Windtree Therapeutics Inc stock remains undervaluedTreasury Yields & AI Forecast for Swing Trade Picks - Bộ Nội Vụ
Windtree Therapeutics Secures $520 Million in Equity Agreements to Expand BNB Cryptocurrency Holdings - MSN
Windtree sells heart drug assets, keeps a cut of any future breakthrough - MSN
Earnings Recap: What analysts say about Windtree Therapeutics Inc stockMarket Risk Summary & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Published on: 2026-01-11 01:19:36 - Улправда
Why Windtree Therapeutics Inc. stock is popular among millennials2025 Support & Resistance & AI Powered Market Trend Analysis - Улправда
Is Windtree Therapeutics Inc. stock trading near support levels2025 Fundamental Recap & Low Volatility Stock Recommendations - Улправда
Is Windtree Therapeutics Inc. stock supported by strong cash flowsQuarterly Risk Review & Free Low Drawdown Momentum Trade Ideas - ulpravda.ru
How Windtree Therapeutics Inc. stock reacts to bond yieldsBear Alert & Free Community Consensus Stock Picks - ulpravda.ru
Does Windtree Therapeutics Inc. stock trade at a discount to peers2025 Technical Patterns & AI Forecasted Entry and Exit Points - Улправда
How interest rate cuts could boost Windtree Therapeutics Inc. stockEarnings Risk Report & Free Growth Oriented Trading Recommendations - Улправда
Will Windtree Therapeutics Inc. stock rally after Fed decisionsJuly 2025 Patterns & Daily Entry Point Alerts - ulpravda.ru
Is Windtree Therapeutics Inc. stock a smart buy before Fed meetingTreasury Yields & Daily Chart Pattern Signals - Улправда
Can Windtree Therapeutics Inc. stock sustain institutional interestQuarterly Performance Summary & Technical Confirmation Alerts - Улправда
Windtree Therapeutics Announces Sudden Departure of President and COO - TipRanks
Windtree Therapeutics Announces Resignation of President and COO - TradingView — Track All Markets
Windtree Therapeutics (OTC: WINT) discloses President and COO resignation - Stock Titan
Windtree Therapeutics, Inc. Announces Resignation of Eric L. Curtis as President and Chief Operating Officer, Effective January 5, 2026 - MarketScreener
Is Windtree Therapeutics Inc. stock a dividend growth opportunityDouble Top/Bottom Patterns & Top Analyst Picks Available for Free - Улправда
How sustainable is Windtree Therapeutics Inc. stock dividend payoutGap Fill Strategies & The Future of Wealth Is Just a Click Away - Улправда
Why Windtree Therapeutics Inc. stock could outperform in 20252026 world cup usa national team round of 32 key players high defensive line winner prediction tactical review - ulpravda.ru
Windtree Therapeutics Receives $7 Million Offer for Preclinical Oncology Platform - MSN
Austin Topic WINDTREE THERAPEUTICS, INC. | News, Weather, Sports, Breaking News - KEYE
Windtree Therapeutics Announces Move into Cryptocurrency Payments and Holdings - MSN
Windtree Sells Heart Drug Assets, Keeps a Cut of Any Future Breakthrough - MyChesCo
Windtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug Candidates - GlobeNewswire
Heart failure drug lineup sold, but seller keeps a slice of future sales - Stock Titan
Trading Recap: How Windtree Therapeutics Inc. stock reacts to bond yields2025 Market Sentiment & Smart Allocation Stock Tips - moha.gov.vn
Why Windtree Therapeutics Inc. stock is rated strong buyQuarterly Profit Report & AI Enhanced Execution Alerts - Улправда
Stock Analysis: Why Windtree Therapeutics Inc. stock is popular among millennials2025 Growth vs Value & Community Driven Trade Alerts - Улправда
Is Windtree Therapeutics Inc. stock a top pick in earnings seasonEarnings Miss & Long Hold Capital Preservation Tips - Улправда
Will Windtree Therapeutics Inc. stock benefit from green energy trendsTrade Analysis Report & Risk Managed Investment Strategies - Улправда
Why Windtree Therapeutics Inc. stock could be next big winner2025 Dividend Review & Advanced Technical Analysis Signals - DonanımHaber
Will Windtree Therapeutics Inc. stock gain from government policiesTrend Reversal & Reliable Price Action Trade Plans - Улправда
Is Windtree Therapeutics Inc. stock attractive for retirement portfoliosTrade Entry Summary & Free High Return Stock Watch Alerts - DonanımHaber
Market Outlook: Why Windtree Therapeutics Inc. stock is rated strong buyJuly 2025 Price Swings & Consistent Income Trade Recommendations - Улправда
Revenue per share of Windtree Therapeutics, Inc. – OTC:WINTW - TradingView — Track All Markets
WINT (Windtree Therapeutics) EV-to-OCF : -0.95 (As of Dec. 18, 2025) - GuruFocus
Windtree Therapeutics Secures Patent in Japan for Cancer Treatment Platform - MSN
Fundamentals Check: Why Windtree Therapeutics Inc stock attracts high net worth investorsWeekly Loss Report & AI Forecast Swing Trade Picks - moha.gov.vn
Windtree Therapeutics Acquires Titan Environmental Services to Drive Profitability - MSN
Windtree Moves Into Fintech With Planned Acquisition of Commercial Lending Platform - MyChesCo
Windtree Therapeutics Delays Quarterly Report Filing - MSN
Warrington’s Windtree Therapeutics Agrees to Buy Fintech Platform CommLoan - BUCKSCO.Today
Windtree Therapeutics to purchase Arizona company - Pennsylvania Business Report -
Windtree Therapeutics Unveils U.S. Exclusivity Strategy for Istaroxime - MSN
Scottsdale-based real estate fintech CommLoan to be acquired by Philadelphia-area firm - The Business Journals
Windtree Showcases Promising Istaroxime Data for Cardiogenic Shock at Major Conference - MSN
Windtree Therapeutics to buy commercial real estate fintech in latest diversification attempt - The Business Journals
Windtree Therapeutics Inc Stock (WINT) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.73%
0.92%
Cap:
|
Volume (24h):